ArticleHuman vaccines & immunotherapeutics2026
Toxicological evaluation of a synthetic QS-21 adjuvant in a tuberculosis vaccine candidate-Demonstrating safety and immunological equivalence to natural reference.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic saponin-based adjuvants hold promise for overcoming the supply instability and purity limitations inherent to naturally derived QS-21. However, establishing their toxicological and functional equivalence to the natural reference is a necessary step before clinical use. This study systematically evaluated the safety and immunogenicity of a recombinant tuberculosis vaccine (named LYB007) formulated with a synthetic QS-21-Api compared to an identical formulation using a naturally-derived reference via single- and repeated-dose toxicity assessments in Sprague-Dawley (SD) rats. Both synthetic and naturally-derived formulations exhibited highly comparable safety and immunological profiles. Injection site reactogenicity was self-limiting, with complete histological resolution by Day 58. Systemic physiological adaptations, including transient thermal shifts and acute-phase protein fluctuations, were consistent with the potent immunostimulatory activity of QS-21 and did not have long-term toxicological significance. Notably, both formulations induced robust, uniform (100%) seroconversion with identical kinetics of antibody development and persistence, with peak geometric mean titers (GMTs) consistently attained between Day 29 and Day 43. The strict seronegativity in negative and mock-vaccine control groups confirmed that the humoral response was exclusively driven by the LYB007-adjuvant complex. Histopathological findings, such as splenic germinal center expansion and extramedullary hematopoiesis, were identified as expected immunological adaptations rather than manifestations of systemic toxicity. In conclusion, these findings confirm that the synthetic QS-21-Api possesses a safety and efficacy profile equivalent to the naturally-derived reference. The use of a chemically defined and standardized adjuvant component overcomes key constraints in vaccine scalability and quality control, supporting the development of future high-efficacy subunit vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.